We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Monday, Mylan NV’s manufacturing partner Meridian Medical Technologies, who is a Pfizer (PFE - Free Report) subsidiary, announced that it will expand its voluntary recall of the EpiPen to the United States after discussing the issue with the Food and Drug Administration (FDA).
This follows Mylan’s recent recall of 81,000 EpiPen devices in countries outside of the U.S. after two reports of the life-saving allergy shot failed to work in emergency situations. Apparently, patients were able to obtain the treatment only after receiving an alternate EpiPen, said Mylan. That recall affected devices distributed throughout Australia, Europe, Japan, and New Zealand.
Mylan believes that the EpiPens being recalled inside the U.S have a defective part like those affected in the initial recall, meaning the autoinjectors will not activate. The generic drug maker cited 13 affected batches of EpiPen 2-Paks and EpiPen Jr. 2-Paks, with expiration dates of April, May, September, and October 2017; these were distributed between December 17, 2015 and July 1, 2016.
“Mylan is committed to replacing recalled devices at no cost and Mylan would like to reassure patients that there will be no additional replacement-related financial burden to them as a result of this recall," said Mylan in a statement.
Mylan came under fire last year after it was revealed that the EpiPen underwent staggering price increases over the years in the U.S., and the company is now the focus of multiple federal investigations.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9x stock explosion after they launched their iPhone in 2007? Now, 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade, which could, in turn, save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Mylan's EpiPen Recall Expanded to U.S.
On Monday, Mylan NV’s manufacturing partner Meridian Medical Technologies, who is a Pfizer (PFE - Free Report) subsidiary, announced that it will expand its voluntary recall of the EpiPen to the United States after discussing the issue with the Food and Drug Administration (FDA).
This follows Mylan’s recent recall of 81,000 EpiPen devices in countries outside of the U.S. after two reports of the life-saving allergy shot failed to work in emergency situations. Apparently, patients were able to obtain the treatment only after receiving an alternate EpiPen, said Mylan. That recall affected devices distributed throughout Australia, Europe, Japan, and New Zealand.
Mylan believes that the EpiPens being recalled inside the U.S have a defective part like those affected in the initial recall, meaning the autoinjectors will not activate. The generic drug maker cited 13 affected batches of EpiPen 2-Paks and EpiPen Jr. 2-Paks, with expiration dates of April, May, September, and October 2017; these were distributed between December 17, 2015 and July 1, 2016.
“Mylan is committed to replacing recalled devices at no cost and Mylan would like to reassure patients that there will be no additional replacement-related financial burden to them as a result of this recall," said Mylan in a statement.
Mylan came under fire last year after it was revealed that the EpiPen underwent staggering price increases over the years in the U.S., and the company is now the focus of multiple federal investigations.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9x stock explosion after they launched their iPhone in 2007? Now, 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade, which could, in turn, save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>